Adam Steensberg

President & Chief Executive Officer, Zeal Pharma

Search every verified Adam Steensberg interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Adam Steensberg, president and CEO of Zealand Pharma, has discussed the company’s obesity drug pipeline, particularly its amylin analog petrelintide, which was partnered with Roche in a deal he described as including a 50/50 profit share and an additional product for Zealand’s pipeline. Steensberg stated that petrelintide could deliver weight loss in a “more pleasant way” than current GLP-1-based treatments, with less nausea and vomiting, and that the drug’s effect of making patients feel full faster could aid in weight maintenance. He described obesity as “the biggest unmet medical need of our times” and said that less than 2% of eligible candidates are currently on treatment, arguing that the market is not saturated and that more large pharmaceutical companies are needed in the space beyond Novo Nordisk and Eli Lilly. Steensberg also commented on the importance of muscle preservation in weight management, stating that maintaining muscle mass could help sustain a higher resting energy expenditure and assist patients in the weight maintenance phase. He noted that Zealand’s focus for its dual-receptor drug dapiglutide will be developing it as a monotherapy for a specific indication initially, rather than as a fixed-dose combination. Regarding the company’s financial position, Steensberg said that Zealand feels “well-armed” to sponsor its share of development and pre-commercial activities under the Roche partnership.